Pet health company Anivive Lifesciences announced it has secured $20 million in funding from Leonid Capital Partners. Leonid is an investment firm focused on high-growth technology companies in the national security industry.
The $20 million investment will help Anivive bolster its research programs, expand its manufacturing capabilities, and drive commercialization of its canine vaccine for Valley fever, the first-ever antifungal vaccine. And Anivive’s direct-to-veterinarian sales platform, Engage, launched in early 2024 and has already processed over 9,000 orders.
This funding comes on the heels of Anivive’s recent $33 million contract with the National Institutes of Health to support the development of a human vaccine against the fungus Coccidioides, which causes Valley fever. Across the pipeline, Anivive now has $80 million in preorders and commitments from industry partners.
Anivive utilizes technology-driven strategies to create novel, affordable healthcare solutions for pets. And through a proprietary AI platform, Anivive accelerates drug discovery and development by repurposing human treatments for veterinary use. Plus, it focuses on tackling life-threatening diseases like pet cancer, feline infectious peritonitis, systemic fungal diseases, and other emerging illnesses.
KEY QUOTES:
“Anivive’s vision to improve and extend the lives of pets aligns perfectly with our mission to empower companies driving meaningful innovation. We’re excited to support their groundbreaking work, which has the potential to transform veterinary care for millions of pets and their families.”
– Chris Lay, Co-Founder of Leonid Capital Partners
“This partnership with Leonid is a significant milestone for Anivive. Their capital allows us to focus on what we do best – developing cutting-edge treatments that will change the way we care for our pets.”
– Dylan Balsz, CEO of Anivive
